Table 5 Demographic data and clinical characteristics of dead versus survivors ILD patients with critical COVID-19
From: Mortality in patients with interstitial lung diseases hospitalized by severe or critical COVID-19
Variable | ILD with critical COVID-19 dead (n = 17) | ILD with critical COVID-19 survivors (n = 10) | P-value |
|---|---|---|---|
Gender women (%) | 12 (70) | 5 (50) | 0.3 |
BMI (kg/m2), IQR | 28 (25–31) | 25 (23–27) | 0.2 |
Diabetes mellitus (%) | 4 (24) | 2 (20) | 0.05 |
Systemic high blood pressure (%) | 7 (41) | 1 (10) | 0.6 |
Smoking (%) | 3 (18) | 3 (30) | 0.09 |
Complete vaccination (%) | 2 (12) | 3 (30) | 0.3 |
Days of hospital stay, IQR | 20 (12–29) | 36 (18–46) | 0.2 |
Days of evolution, IQR | 9 (5–12) | 16 (7–23) | 0.01 |
PaO2/FiO2, IQR | 140 (93–172) | 176 (130–242) | 0.05 |
Leukocytes absolute number(10^3/mm3), IQR | 9 (8–11) | 12 (6–14) | 0.2 |
Neutrophiles absolute number(10^3/mm3), IQR | 8 (6–9) | 10 (6–13) | 0.2 |
Lymphocytes absolute number(10^3/mm3), IQR | 0.7 (0.3–0.9) | 0.6 (0.3–1) | 0.2 |
CRP (mg/dL), IQR | 17 (12–23) | 19 (10–25) | 0.9 |
Procalcitonin (ng/mL), IQR | 1 (0.1–1.3) | 0.4 (0.04–0.5) | 0.6 |
Ferritin (ng/mL), IQR | 1207 (449–1688) | 1561 (429–2085) | 0.2 |
Fibrinogen (mg/dL), IQR | 681 (656–771) | 736 (686–956) | 0.8 |
D-Dimer (μg/dL), IQR | 3 (1–5) | 7 (0.4–4) | 0.6 |